Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Qiagen ( (QGEN) ).
QIAGEN N.V. announced a managerial transaction involving Thierry Bernard, a member of its managing body, who sold shares worth approximately $1.23 million on the NYSE. The sale was conducted for asset allocation and tax payments, reflecting typical financial management strategies within the company. This transaction may impact stakeholders’ perception of the company’s financial strategies and managerial decisions.
The most recent analyst rating on (QGEN) stock is a Hold with a $42.50 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its innovative solutions that enable customers to gain valuable insights from biological samples.
Average Trading Volume: 1,463,714
Technical Sentiment Signal: Buy
Current Market Cap: $10.69B
For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.